RenovoRx, Inc. announced that the University of Texas (UT) Southwestern Medical Center is now enrolling pancreatic cancer patients in the open label, randomized Phase III TIGeR-PaC clinical trial. The study is investigating RenovoGem which utilizes RenovoRx's proprietary therapy platform, TAMP(TM), to provide improved and targeted intra-arterial delivery of FDA-approved gemcitabine chemotherapy to treat Locally Advanced Pancreatic Cancer (LAPC). RenovoGem is the first drug-device combination product candidate that utilizes the TAMP(TM) therapy platform via pressure-mediated delivery technology to deliver gemcitabine, an FDA-approved chemotherapy, locally across the arterial wall to bathe tumor tissue in the chemotherapy.

RenovoGem is currently being evaluated in the open label, randomized phase III TIGeR- PaC clinical trial study in Locally Advanced Pancreatic cancer (LAPC) patients. The Company plans to investigate RenovoGem in extrahepatic Cholangiocarcinoma (eCCA) in a clinical trial, which is anticipated to begin in the first half of 2023.